0.45
-4.26%
Close of 6 Nov 2026, in SGD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IX Biopharma
Its shares trade on SGX under the ticker 42C.SI. It has been listed since 22 July 2015. In the fiscal year to 30 June 2026, it reported revenue of SGD 6.9m and a net loss of SGD 8.0m. At that date it held total assets of SGD 25.9m and shareholders' equity of SGD 15.4m.
iX Biopharma Ltd. engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. The company employs 56 full-time employees The company went IPO on 2015-07-22. The firm is engaged in the development, manufacture and commercialization of therapies for the treatment of acute and breakthrough pain, and male erectile dysfunction. Its segments include Specialty Pharmaceutical and Chemical Analysis segments. The Specialty Pharmaceutical segment is engaged in the development, manufacturing and sale of pharmaceutical products. The Chemical Analysis segment is engaged in the provision of laboratory testing services. Its products are Wafermine, which is a sublingual ketamine oral wafer that contains the non-opioid drug for the management of moderate to severe pain; Bnox, which is a sublingual buprenorphine oral wafer that is developed as a formulation for moderate to severe pain; PheoniX, which is used for the treatment of male erectile dysfunction; WaferRest, which is used for the alleviation of jet lag and improving sleep quality, and Wafernyl, which is used for breakthrough cancer pain.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Jul 2015
- Employees
- 56
- Website
- ixbiopharma.com ↗
Leadership
Pay as last reported
- Mr. Yip Hang LeeExecutive Chairman of the Board, Chief Executive Officer, since 2008
- Mr. Sien Lup ChewChief Financial Officer
- Dr. Janakan KrishnarajahChief Operating Officer, Chief Medical Officer
- Dr. Iain CookChief Scientist
- Dr. Stephen LimChief Pharmacist
- Ms. Yi Hua TanChief Commercial Officer
- Mr. Kuan Loong LaiJoint Company Secretary
- Ms. Soo Fern LeeJoint Company Secretary
- Mr. Patrick DaviesNon-Executive Lead Independent Director
- Mr. Shing Tung HoNon-Executive Director
- Mr. Woon Keng TeoNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IX Biopharma Ltd has a strong portfolio of innovative pharmaceutical products that cater to a diverse range of therapeutic areas. These products have shown promising results in clinical trials, showcasing the company's strong research and development capabilities.
- The company has established strategic partnerships with leading healthcare organizations, enabling IX Biopharma Ltd to leverage their extensive networks and resources for market expansion, distribution, and access to new markets.
- IX Biopharma Ltd has a robust intellectual property portfolio, providing protection for their innovative drug formulations and delivery technologies. This strengthens the company's competitive position and offers barriers to entry for potential competitors.
Weaknesses
- One of the challenges IX Biopharma Ltd faces is the dependency on a limited number of key customers. This can expose the company to potential risks if any of these customers significantly reduce their orders or switch to alternative suppliers.
- The company has relatively limited financial resources compared to some of its competitors, which may restrict their ability to invest in new product development initiatives or expand market presence at the desired pace.
- There might be a lack of brand awareness and recognition in certain geographical markets, which could pose difficulties in penetrating these regions and competing effectively against established pharmaceutical companies.
Opportunities
- The increasing prevalence of various diseases and the growing demand for novel pharmaceutical solutions present significant opportunities for IX Biopharma Ltd to expand its market share and generate substantial revenue growth.
- The company can capitalize on advancements in technology and scientific research to develop new and improved drug delivery systems, maximizing the effectiveness and convenience of their pharmaceutical products.
- Emerging markets, particularly in developing countries, offer untapped potential for IX Biopharma Ltd to establish a stronger presence and capture a larger customer base by offering affordable yet quality healthcare solutions.
Threats
- The pharmaceutical industry is highly regulated, and changes in regulations or pricing policies imposed by regulatory authorities could impact IX Biopharma Ltd's operations, cost structure, and profitability.
- Intense competition within the industry from established pharmaceutical companies and new entrants poses a threat to IX Biopharma Ltd's market position and revenue growth. The company needs to continuously innovate and differentiate its products to stay ahead.
- Economic uncertainties and volatility may affect consumer spending patterns, leading to reduced demand for pharmaceutical products and potential challenges in maintaining steady revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.